Fulcrum Therapeutics announced that Esther Rajavelu has resigned from her position as chief financial officer, CFO, and treasurer effective April 21, 2023. Rajavelu will serve in a consulting role to ensure the continuity of Fulcrum’s financial operations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics Announces CFO Resignation
- Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Fulcrum Therapeutics price target lowered to $10 from $18 at SVB Securities
- Fulcrum Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- Fulcrum Therapeutics downgraded to Neutral from Outperform at Credit Suisse
